CONSTANT LEVERAGE LONG - GALAPAGOS Stock

ZU5FB

NLBNPNL1S6E7

Market Closed - Euronext Paris 12:30:01 2024-05-31 pm EDT
0.001 ^EUR	-.--%

6 months	-90.91%
Current year	-94.74%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GALAPAGOS NV

Chart CONSTANT LEVERAGE LONG - GALAPAGOS

Latest news about GALAPAGOS NV

Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	May. 31	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	May. 31	MT
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so	May. 31	PU
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	May. 30	GL

More news

Quotes 5-day view

Date	Price	Change
24-05-30	0.001	-.--%
24-05-29	0.001	-.--%
24-05-28	0.001	-.--%
24-05-27	0.001	-.--%
24-05-24	0.001	-.--%

Real-time Euronext Paris

Last update May 31, 2024 at 12:30 pm EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	GALAPAGOS NV
Issuer	BNP Paribas
	ZU5FB
ISIN	NLBNPNL1S6E7
Date issued	2022-04-11
Maturity	Unlimited
Parity	1 : 1
Emission price	- €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	6.54 €
Lowest since issue	0.001 €

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

More about the company

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Galapagos NV

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

25.74 EUR

Average target price

37.03 EUR

Spread / Average Target

+43.86%

Consensus